The Biologics Market is led by North America, which held more than 45% of the global market in 2024. The region benefits from advanced healthcare infrastructure, strong pharmaceutical R&D investment, and an established biotechnology ecosystem.

Asia-Pacific is emerging as a major growth region, accounting for approximately 20% of the global market. China and India are investing in biotechnology, pharmaceutical manufacturing, and healthcare infrastructure, supporting increased adoption of biologic medicines.

Europe also remains an important market because of its established pharmaceutical industry and regulatory environment. Meanwhile, the Middle East and Africa offer longer-term opportunities as healthcare investment and access to advanced therapies improve.

Major companies identified by Market Research Future include AbbVie, Amgen, Roche, Johnson & Johnson, Novartis, Bristol-Myers Squibb, Sanofi, Gilead Sciences, and Merck & Co.

With continued advances in biotechnology, personalized medicine, biosimilars, and automated biomanufacturing, the global biologics industry is expected to remain a major area of pharmaceutical innovation through 2035